Participant Basic Agreement (PBA) Opportunity - Threat Agnostic Host-Directed Therapeutics
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The Capability Program Executive for Chemical, Biological, Radiological, and Nuclear Defense (CPE CBRND) invites participation in the HEALER portfolio, a next-generation initiative for threat-agnostic, host-directed medical countermeasures. This program seeks to develop therapeutics that enhance the body's ability to withstand and recover from CBRN threats, offering dual-use commercial opportunities. Interested parties should submit a white paper for consideration under a Participant Basic Agreement (PBA).
Scope of Work
The HEALER portfolio aims to build threat-agnostic host resilience by developing therapeutics that provide layered physiological protection. The program focuses on targeting one or more of the following critical host systems:
- Neurological Protection
- Respiratory Stabilization
- Immune Modulation
- Hematologic & Vascular Function
- Cellular Stress & Repair Pathways
Contract & Timeline
- Type: Participant Basic Agreement (PBA)
- Authority: 10 U.S.C. §§ 4021, 4022, and 4023 (not subject to Competition in Contracting Act)
- Published: April 23, 2026
Submission & Evaluation
This opportunity is open to the full spectrum of drug development organizations, including:
- Therapeutic Development Collaborators: Developers of host-directed therapeutic candidates.
- Drug Development Support Collaborators: Organizations specializing in CROs/CDMOs, preclinical testing, clinical trials, cGMP manufacturing, regulatory submissions, and advanced modeling.
Interested entities must submit a white paper (not to exceed five pages, excluding cover page). Submissions should detail product descriptions, efficacy data, regulatory/clinical status, manufacturing capabilities, and company profiles for therapeutic developers. Service providers should summarize core capabilities, relevant experience, infrastructure, and technology. Companies should also state their willingness to team or collaborate with other PBA holders.
Eligibility / Set-Aside
This opportunity is open to all drug development organizations; no specific set-aside is designated.
Additional Notes
Prospective awardees MUST be registered in the System for Award Management (SAM) database prior to submitting an invoice and through final payment. All technical and administrative questions should be directed to Hunter Robinson (hunter.t.robinson4.civ@army.mil) or Alexander Mayatte (alexander.z.mayatte.civ@army.mil).